Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN1A | P35498 | 3/20 | 0.53 |
| ▸ | SCN8A | Q9UQD0 | 3/20 | 0.53 |
| ▸ | SCN5A | Q14524 | 2/20 | 0.52 |
| ▸ | SCN9A | Q15858 | 17/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL21955515 | 0.99 | SCN1A (0.52) | SCN1ASCN8ASCN5ASCN9ACYP2C9 | |
| SCHEMBL28556000 | 0.82 | SCN1A (0.49) | SCN1ASCN8ASCN5ASCN9ACYP2C9 | |
| SCHEMBL21777479 | 0.81 | SCN8A (0.57) | SCN1ASCN8ASCN5ASCN9A | |
| SCHEMBL31017728 | 0.79 | SCN1A (0.47) | SCN1ASCN8ASCN5ASCN9ACYP2C9 | |
| SCHEMBL21783416 | 0.75 | SCN1A (0.55) | SCN1ASCN8ASCN5ASCN9A | |
| SCHEMBL21783429 | 0.75 | SCN1A (0.58) | SCN1ASCN8ASCN5ASCN9ACYP2C9 | |
| Hydrochloric Acid SCHEMBL30045377 | 0.74 | SCN1A (0.57) | SCN1ASCN8ASCN5ASCN9ACYP2C9 | |
| Hydrochloric Acid SCHEMBL21955494 | 0.74 | SCN1A (0.57) | SCN1ASCN8ASCN5ASCN9ACYP2C9 | |
| Hydrochloric Acid SCHEMBL21955493 | 0.73 | SCN1A (0.56) | SCN1ASCN8ASCN5ASCN9ACYP2C9 | |
| SCHEMBL21783509 | 0.72 | BACE1 (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11639351-B2 | Heteroaryl-substituted sulfonamide compounds and their use as therapeutic agents | XENON PHARMACEUTICALS INC. | 2023-05-02 | — | — | US | disclosed |
| US-10981905-B2 | Heteroaryl-substituted sulfonamide compounds and their use as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2021-04-20 | — | — | US | disclosed |
| US-20200157089-A1 | HETEROARYL-SUBSTITUTED SULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2020-05-21 | — | — | US | disclosed |
| WO-2020047323-A1 | HETEROARYL-SUBSTITUTED SULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2020-03-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11639351-B2 | Heteroaryl-substituted sulfonamide compounds and their use as therapeutic agents | SCN1A, SCN2A, SCN2B | SCN1A 1/4885SCN8A 6/4885SCN5A 7/4885 |
| US-20200157089-A1 | HETEROARYL-SUBSTITUTED SULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | SCN1A, SCN2A, SCN2B | SCN1A 1/4885SCN8A 6/4885SCN5A 7/4885 |
| US-10981905-B2 | Heteroaryl-substituted sulfonamide compounds and their use as therapeutic agents | SCN1A, SCN2A, SCN2B | SCN1A 1/4885SCN8A 6/4885SCN5A 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.